Skip to content

Screening for 3-D Visual Disorders in Preschool Children

Screening for 3-D Visual Disorders in Preschool Children, VISION Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05204069
Acronym
VISION
Enrollment
95
Registered
2022-01-24
Start date
2021-01-01
Completion date
2021-09-01
Last updated
2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amblyopia, Anisometropia, Strabismus

Brief summary

Visual screening is necessary among pre-school children as they found themselves in a critical period of visual developement. To date, there are no national vision screening program that has been implemented nationwide. Vision is a pilot feasibility multicentric cluster study comparing the sensitivity of AFSOP 3 dimensional visual screening protocol in a population of 3 to 4-year-old pre-school children conducted in 4 kindergarten preschools in Paris with gold-standard ophthalmic examination confirmation.

Detailed description

Visual screening is necessary among pre-school children as they found themselves in a critical period of visual developement. To date, there are no national vision screening program that has been implemented nationwide. Methodology: The Association Française de Strabologie et d'Ophtalmologie Pédiatrique AFSOP proposed criteria based on a 3-dimensions visual screening to assess whether or not a child presents risk factors of amblyopia such as ametropia, strabismus and anisometropia. Vision is a pilot feasibility multicentric cluster study comparing the sensitivity of AFSOP 3 dimensional visual screening protocol in a population of 3 to 4-year-old pre-school children conducted in 4 kindergarten preschools in Paris with gold-standard ophthalmic examination confirmation. Expected results: We assume that a vision screening operated with the AFSOP 3 dimension screening recommendations and conducted by paramedical actors such as orthoptists will prove more sensitive and easier to implement on a national scale.

Interventions

DRUGInstillation of cyclopentolate

Instillation of cyclopentolate of 3 drops of cyclopentolate at t0',t5' and t10' with to induce a certain level of cycloplegia and evaluate manifest refraction at t45' using the RetinoMax Device.

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
3 Years to 4 Years
Healthy volunteers
Yes

Inclusion criteria

* Children aged 3 to 4 years * Enrolled in kindergarten in the first section * In the 19th district of Paris * Who should benefit from visual screening via the school medical service

Exclusion criteria

* Children who do not speak French * Children who are physically or cognitively unable to participate in the screening

Design outcomes

Primary

MeasureTime frameDescription
Screening for 3-dimensional visual disorders1 daySensitivity of the AFSOP 3-dimensional screening vs PARIS protocol screening using a comprehensive ophthalmological examination as a gold standard

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026